Overview

A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

Status:
Not yet recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.